





MediPrint Ophthalmics employs a 3Dprinting technology to print FDA-approved drugs onto FDA-approved lenses.



 $R_T = R_A * R_B * R_C$







Barrier layers can be printed on a drug reservoir layer to modulate the drug release rate, as shown above.

Importantly, all MediPrint Ophthalmics' products are manufactured preservative-free, eliminating a major adverse effect of eyedrops.

Additionally, a cornerstone of MediPrint's products is the release of **Hyaluronic** Acid, a natural lubricant that keeps the eye moist during lens wear


Simultaneous and Sustained Delivery of Bimatoprost and HA from Contact Lenses: A Preliminary Study on Glaucoma, Dry Eye, and Lens-Related Discomfort

Robert Davis, O.D., F.A.A.O, Houman Hemmati, M.D., and Rajeev Garg, Ph.D. MediPrint Ophthalmics Inc., San Diego, CA; CBCC, Bakersfield, CA


PRECLINICAL RESULTS

In-Vivo Drug Release Results: A

pharmacokinetic study found Bimatoprost and bimatoprost free acid in rabbit tear samples up to 8 days, which confirmed the sustained release of bimatoprost for one week.




Hyaluronic Acid Release Results: HA was released in simulated tear fluid up to 8 days or 192 hours. MediPrint lenses released more than twice the amount of HA as the control, hydrogel lenses soaked in BioTrue[™] Multi-Purpose solution.



In the test arm, a sustained, clinically significant reduction in IOP was achieved for three weeks. IOP shown for test and reference for both eyes shown below:

CLINICAL RESULTS

	Test (MediPrint® 26 μg contact lens, x1/week)	Reference (Timolol 0.5% topical eye drops, x2/day)
Mean IOP ¹ Change from Baseline (Week 3)	-5.5	-6.7
Clinically meaningful reduction in IOP	Yes	Yes
Number of instillations in 3 weeks (both eyes)	6	84
Preservative-free	Yes	No
	N=11	N=14




SAFETY AND TOLERABILITY

- Of 14 patients, 11 finished trial.
- No serious treatment emergent adverse events were observed
- No contact lens protein deposits were observed on either eye for any subject
- No external comfort agents were used during trial

During the three-week trial, **discomfort** and **dry** eye scores as per CLDEQ-8 improved by 68% and 23%, respectively.

EFFECT OF HYALURONIC ACID



With 3 weeks of LL-BMT1

CONCLUSIONS

In the clinical study, a statistically significant IOP drop of 5.5 mmHg was sustained for three weeks Lenses were inserted just 6 times over three weeks, a 93% reduction in treatment frequency. LL-BMT1 was found to be safe and tolerable. There were no serious TEAEs observed. With sustained delivery of HA, comfort increased by 68%, and dry eye improved by 23%. Additional studies are in progress, with higher doses on LL-BMT1, to further optimize efficacy of product.

Results from interim analysis are FDA-approvable and validates our platform technology.